Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
Renovorx Inc (RNXT) pioneers targeted therapeutic delivery systems designed to transform cancer treatment and vascular interventions through its proprietary Trans-Arterial Micro-Perfusion technology. This page serves as the definitive source for verified updates about the clinical-stage innovator’s progress in precision medicine.
Investors and medical professionals will find comprehensive coverage of FDA clearances, clinical trial milestones, and strategic partnerships. Track developments in RNXT’s pipeline including oncology-focused device innovations and evidence-based research validating its Renovocath™ delivery platform.
Key updates include regulatory submissions, peer-reviewed study results, manufacturing collaborations, and financial performance reports. All content is curated to support informed analysis of RNXT’s position in the competitive medical device sector while adhering to strict journalistic standards.
Bookmark this page for streamlined access to essential RNXT developments. Combine our real-time updates with Stock Titan’s financial tools to monitor this innovator in localized therapeutic delivery systems.
RenovoRx, Inc. (Nasdaq: RNXT) announced promising interim results from the Phase III TIGeR-PaC clinical trial for its product candidate, RenovoGem, aimed at treating locally advanced pancreatic cancer (LAPC).
The interim analysis indicates a 6-month increase in median overall survival in the RenovoGem group (16 months) compared to standard care (10 months). The trial is randomized, with 114 patients expected, and the current analysis included 45 patients. The Data Monitoring Committee recommends continuing the trial, with full data to be presented at the AACR Annual Meeting on April 17, 2023.
RenovoRx (Nasdaq: RNXT) reports financial results for 2022 and updates on its Phase III TIGeR-PaC clinical trial for localized pancreatic cancer treatment. The company has randomized 47 out of 114 patients, triggering its first interim analysis after recording 26 events (deaths). RenovoRx anticipates releasing the interim analysis results soon. Financially, cash and equivalents were $6.4 million at year-end, with total assets of $7.3 million against liabilities of $1.1 million. The company's net loss was $9.9 million, with a loss per share of ($1.09). Operating expenses increased to $10 million, driven by R&D and admin costs.
RenovoRx, a biopharmaceutical company focused on localized cancer treatment, announced CEO Shaun Bagai will present at the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, California. Bagai will discuss the company's lead product candidate, RenovoGem™, which aims to disrupt standard chemotherapy with targeted intra-arterial delivery using the proprietary RenovoTAMP® platform. The pivotal Phase III TIGeR-PaC clinical trial for RenovoGem is ongoing, with the first interim analysis expected soon. RenovoRx also plans to investigate RenovoGem for extrahepatic cholangiocarcinoma in 2023.
RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company, announced that CEO Shaun Bagai will virtually present at the Sequire Biotechnology Conference on February 2, 2023, at 4 p.m. (ET). The presentation will focus on RenovoRx's innovative RenovoTAMP® therapy platform, which aims to transform cancer treatment by delivering localized chemotherapy directly to solid tumors, improving patients' quality of life. Bagai will also discuss the ongoing Phase III TIGeR-PaC clinical trial targeting locally advanced pancreatic cancer, with the first interim analysis expected soon. The event is open to the public for registration.
RenovoRx, Inc. (Nasdaq: RNXT) announced initial results from a pharmacokinetic substudy within the phase III TIGeR-PaC clinical trial at the 2023 ASCO GI Cancers Symposium. This trial evaluates the intra-arterial administration of gemcitabine for treating Locally Advanced Pancreatic Cancer (LAPC) using the RenovoTAMP platform. Preliminary findings indicate that the RenovoTAMP method may reduce systemic drug exposure by over 50%, potentially minimizing side effects while enhancing local chemotherapy delivery. Three additional supportive abstracts will also be presented, advancing the understanding of pancreatic cancer treatment.
RenovoRx, Inc. (NASDAQ: RNXT) announced the issuance of US patent number 11,541,211 on January 3, 2023, covering methods for treating cholangiocarcinoma through targeted delivery of therapeutic agents. This patent is their eighth in the US, contributing to a robust intellectual property portfolio that includes 8 US method and device patents, one EU delivery system patent, and several pending patents globally. Additionally, the patent strengthens the seven years of market exclusivity RenovoRx holds for its lead product candidate, RenovoGem™, under FDA's Orphan Drug designation.
RenovoRx, Inc. (Nasdaq: RNXT) announced the acceptance of four clinical data abstracts supporting its lead oncology candidate, RenovoGem, at the 2023 ASCO Gastrointestinal Cancers Symposium, scheduled for January 19-21, 2023, in San Francisco, California.
RenovoGem, evaluated in a Phase III trial for Locally Advanced Pancreatic Cancer (LAPC), employs a proprietary delivery system via RenovoTAMP. Upcoming plans include an interim analysis of the TIGeR-PaC study and investigations into extrahepatic Cholangiocarcinoma (eCCA).
RenovoRx (Nasdaq: RNXT) announced that its therapy platform, RenovoTAMP, was featured in two presentations at the Advanced Interventional Management Symposium. Dr. Ripal Gandhi discussed the potential of RenovoTAMP for treating locally advanced pancreatic cancer (LAPC), emphasizing a Phase III study, TIGeR-PaC, aimed at extending survival and reducing side effects. Dr. Christopher Laing explored RenovoTAMP's applications in pancreatic and bile duct cancers. The company aims to enhance chemotherapy delivery while minimizing toxicity, holding Orphan Drug Designation for its treatment approaches.
RenovoRx, Inc. (NASDAQ: RNXT) reported its financial results for Q3 2022, highlighting a net loss of $2.1 million, up from $1.5 million in Q3 2021. Cash and equivalents stood at $8.1 million as of September 30, 2022. The company plans to conduct a prospective interim analysis of its Phase III TIGeR-PaC trial for pancreatic cancer treatment, potentially revolutionizing care in this area. A new clinical trial for extrahepatic cholangiocarcinoma is also set to launch in late 2022 or early 2023. General and administrative expenses increased to $1.3 million amid higher consulting costs.
RenovoRx, Inc. (Nasdaq: RNXT) announced CEO Shaun Bagai will participate in a ROTH Capital webinar on October 27 at 1 p.m. ET. The discussion will focus on RenovoRx's mission to innovate oncology therapy through its RenovoTAMP treatment, which aims to improve quality of life and enhance survival for patients with difficult-to-treat cancers. Bagai will also review the ongoing Phase 3 TIGeR-PaC clinical trial, with its first results expected in Q4 2023. The public can register to attend and ask questions during the session.
FAQ
What is the current stock price of Renovorx (RNXT)?
What is the market cap of Renovorx (RNXT)?
